← Back to patent-cliff list
盐酸乐卡地平
Tier C — Watch / tradeLercanidipine Hydrochloride
Recordati
Originator
1996
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：VDCCs
Brand：Renovia、Vasodip、Lercadip、Carmen、Lercan、Lercaton、Lerdip、Lercapin、Cardiovasc、Corifeo、Lerkamen、Zanicor、Lerzam、Zanedip、Zandip、Zanidip
Indications (approved)：高血压
Regional status
US
-
EU
批准上市
1996-03-22
China
批准上市
2010-08-04
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lercanidipine Hydrochloride?
Approved indications include: 高血压.
When does the Lercanidipine Hydrochloride patent expire?
No public expiry year is available for Lercanidipine Hydrochloride yet; this page updates once verified.
How do I get a quote for Lercanidipine Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25